Correspondence on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study by Smeenk et al 23 de July de 2025 by Wang, B.-C.
Bevacizumab combined with chemotherapy and anti-PD-1 therapy for the first-line treatment of previously untreated metastatic triple-negative breast cancer 30 de April de 2025 by Wang, B.-C.
Letter to the editor: safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria 21 de March de 2025 by Wang, B.-C.
Letter to the editor: effects of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer–a prospective observation study 6 de February de 2025 by Wang, B.-C.
Wang, B.-C. 